Not only that, but there is already a phase 2 study program, using it for the targeting of patients with Asthma. However, ...

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...

Asthma affects more than 260M people worldwide and nearly 28M people in the U.S. alone, where, on average, 10 people die from attacks of the chronic disease each day. Many of these deaths could be ...